Oasmia Pharmaceutical and Abbott Sign Global Collaboration Agreement for Canine Oncology Therapies

   Oasmia Pharmaceutical and Abbott Sign Global Collaboration Agreement for
                          Canine Oncology Therapies

PR Newswire

UPPSALA, Sweden, January 7, 2013

UPPSALA, Sweden, January 7, 2013 /PRNewswire/ --

Oasmia and Abbott have entered into an exclusive global collaboration
agreement with respect to Oasmia's two leading animal health product
candidates, Paccal® Vet and Doxophos® Vet. The agreement significantly expands
the nature and scope of the initial collaboration that was initially entered
into in 2009 between Oasmia and Abbott regarding these products.

Under the terms of the expanded agreement, Abbott Animal Health will obtain
exclusive license and distribution rights to the products for essentially the
entire world. In return, Oasmia will receive an upfront payment and is
eligible to receive additional milestone payments of up to $21.5M subject to
Oasmia meeting various product development and sales milestones. In addition,
in the event either or both of the products are commercialized, Oasmia shall
receive tiered royalties on net sales. Oasmia will continue to fund research,
development and manufacture of Paccal® Vet and Doxophos® Vet.

"I am very pleased that we have reached this expanded agreement between our
companies. We will now have one world-class partner for essentially the entire
global canine oncology market. In addition to the well-established markets in
the industrialized countries, we believe that there is great future market
potential in developing countries as medical innovation allows dedicated
owners to treat emerging health issues in their beloved companion animals,"
said Julian Aleksov, chief executive officer, Oasmia Pharmaceutical.

The agreement does not include the rights to Paccal® Vet in Russia, Japan and
the Commonwealth of Independent States (CIS), or the rights to Doxophos® Vet
in Russia and the CIS.

Cancer is the leading cause of canine disease-related deaths, with up to 3
million new cases diagnosed annually worldwide. Cancer accounts for nearly 50
percent of all deaths in dogs 10 years of age or older.

Information is also available at

SOURCE Oasmia Pharmaceutical AB

Contact: For more information, please contact: Johan Edin, acting Head of
Public Relations, Oasmia Pharmaceutical AB. E-mail: press@oasmia.com Phone:
+46-(0)18-50-54-40. German contact: Dr. Sönke Knop, Peggy Kropmanns, edicto
GmbH, Frankfurt E-Mail: oasmia@edicto.de Phone: +49-(0)69-90-55-05-52.
Press spacebar to pause and continue. Press esc to stop.